Intelligent Bio Solutions (INBS) Expected to Post Quarterly Earnings on Wednesday

Intelligent Bio Solutions (NASDAQ:INBS) is anticipated to announce its Q1 2027 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($1.31) per share and revenue of $1.40 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Intelligent Bio Solutions Trading Up 6.6%

NASDAQ INBS opened at $1.77 on Wednesday. The stock’s 50-day moving average price is $1.85 and its two-hundred day moving average price is $3.17. The company has a market cap of $5.88 million, a PE ratio of -0.20 and a beta of 4.48. Intelligent Bio Solutions has a 1 year low of $1.35 and a 1 year high of $24.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Intelligent Bio Solutions has a consensus rating of “Reduce”.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc (NASDAQ: INBS) is a life sciences company focused on developing and commercializing non-invasive diagnostic and screening technologies. Its primary product is the Intelligent Bio Solutions Drug Screening System, a portable platform designed to detect drugs of abuse through sweat collected from a person’s fingerprint.

The system uses a disposable drug screening cartridge and a handheld reader to analyze fingerprint sweat and provide results rapidly. The company markets the technology for applications such as workplace testing, law enforcement, rehabilitation programs, and other settings that require convenient, observed drug screening.

Intelligent Bio Solutions was formerly known as GBS Inc and adopted its current name following its acquisition and integration of Intelligent Fingerprinting, a United Kingdom-based developer of fingerprint-based drug screening technology.